Albuquerque, NMNCT06105892Now EnrollingIRB Ready

Convergence Insufficiency Clinical Trial in Albuquerque, NM

Access cutting-edge convergence insufficiency treatment through this clinical trial at a research site in Albuquerque. Study-provided care at no cost to qualified participants.

Sponsored by New Jersey Institute of Technology

Quick Self-Assessment

See if you qualify for this Albuquerque location

Preparing your pre-screening questions…

Expert Care in Albuquerque

Access convergence insufficiency specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related convergence insufficiency treatment provided free

Apply for This Albuquerque Location

Check if you qualify for this convergence insufficiency clinical trial in Albuquerque, NM

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Albuquerque

    Convenient for NM residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Albuquerque site if eligible
  4. 4Begin participation

About This Convergence Insufficiency Study in Albuquerque

This study will test a portable virtual reality (VR) system with integrated eye tracking called Virtual Eye Rotation Vision Exercises (VERVE). The proposed VERVE platform will deliver vergence therapy in an automated manner. This research will involve 30 non-traumatic brain injury (TBI) binocularly normal (BNC) Veterans and 50 post-traumatic convergence insufficiency (PTCI) Veterans who will undergo Active and Sham therapy (equally divided groups) to determine the effectiveness of VERVE vergence therapy.

Sponsor: New Jersey Institute of Technology

Who Can Participate

Inclusion Criteria

are aged 18 - 40;
have suffered a mTBI according to VA/Department of Defense (DoD) criteria with documented evidence of alteration of consciousness (AOC) \< 24 hours or loss of consciousness (LOC) less than 30 minutes;
were injured between 1 month and 15 years ago;
received a Glasgow coma scale (GCS) score of between 13 and 15 upon emergency department (ED) admission, if available;
experienced less than 24 hours of post-traumatic amnesia (PTA), if any;
have ongoing post-concussive symptoms as evidenced by a score of 18 or greater or a score of 2 or greater on question 6 (vision problems, blurring, trouble seeing) on the Neurobehavioral Symptom Inventory (NSI);
have ongoing vision-related symptoms as evidenced by a score of 31 or higher on the Brain Injury Vision Symptom Survey (BIVSS);
have PTCI as evidenced by obtaining a score of 21 or higher on the convergence insufficiency symptom survey (CISS), a specific measure of convergence insufficiency;
are fluent in English; and
have been on stable doses of any vision-altering medications for the past 2 months.
Stereopsis of 500 sec arc using Randot Stereo Test.
Exophoria at near 4 prism-diopter (PD) or greater than magnitude at distance
Near point of convergence (NPC) \> 5 cm
Convergence amplitude at near \< 15PD break or the Sheard criterion not met Control Inclusion Criteria:
are aged 18 - 40;
CISS score of 20 or lower;
near point of convergence (NPC) \< 6cm; and
positive fusional range \>15 prism diopters.
Stereopsis of 500 sec arc using Randot Stereo Test.

Exclusion Criteria

prior history of other neurological diseases, so as to reduce the risk of confounding effects on vision;
history of psychosis, as there are known visual performance findings associated with psychosis;
history of current or recent (within two years) substance/alcohol dependence, to reduce confounding effects on visual function
recent medical hospitalization (within three weeks), to reduce risk of rehospitalization during the study;
any condition that would prevent the participant from completing the protocol;
appointment of a legal representative, to avoid coercion of a vulnerable population;
any ongoing litigation related to TBI, to prevent interference with legal proceedings;
membership in an identified vulnerable population, including minors and prisoners, so as to prevent coercion.
Previous vergence therapy, orthoptics, home-based therapy, etc.
Amblyopia or constant strabismus or strabismus surgery.
High refractive error: Myopia ≥ 6.0PD sphere; Hyperopia ≥ 5.0PD sphere; Astigmatism ≥ 4.0PD; Anisometropia \>1.5PD difference between eyes; Prior refractive surgery.
Manifest or latent nystagmus evident clinically.
Systemic diseases that affect accommodation, vergence, or ocular motility (i.e. multiple sclerosis, Graves' thyroid disease, myasthenia gravis, diabetes, chemotherapy or Parkinson disease).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Albuquerque?

Yes, this clinical trial (NCT06105892) has an active research site in Albuquerque, NM that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Convergence Insufficiency Treatment Options in Albuquerque, NM

If you're searching for convergence insufficiency treatment options in Albuquerque, NM, this clinical trial (NCT06105892) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Albuquerque research site is actively enrolling participants for this clinical trial. You'll receive care from experienced convergence insufficiency specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all convergence insufficiency clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Albuquerque, NM

See all interstitial cystitis clinical trials recruiting in Albuquerque — not just this study.

Browse Interstitial Cystitis Trials in Albuquerque →

Browse More Trials by Condition

Interstitial Cystitis TrialsAll Conditions →

Ready to Join in Albuquerque?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Albuquerque, NM